A Comprehensive Monograph on Tramadol (DrugBank ID: DB00193): Pharmacology, Clinical Use, and Safety Profile

Executive Summary

Tramadol is a centrally-acting synthetic analgesic used for the management of moderate to moderately severe pain in adults. Identified by DrugBank ID DB00193 and CAS Number 27203-92-5, it is classified as a small molecule drug. Its clinical utility is derived from a unique, dual mechanism of action that distinguishes it from traditional opioid analgesics. Tramadol functions as a weak agonist at the µ-opioid receptor and simultaneously inhibits the reuptake of serotonin and norepinephrine (SNRI), thereby modulating both opioid-mediated and monoaminergic descending pain pathways. This multimodal activity contributes to its efficacy across a spectrum of pain conditions, including neuropathic and chronic pain, and positions it as a Step 2 option on the World Health Organization's pain ladder.

The drug is administered as a racemic mixture of its (+)- and (-)-enantiomers, which act synergistically. The (+)-enantiomer and its primary active metabolite, O-desmethyltramadol (M1), are responsible for the µ-opioid receptor agonism and serotonin reuptake inhibition, while the (-)-enantiomer primarily inhibits norepinephrine reuptake. The conversion of tramadol to the more potent M1 metabolite is critically dependent on the cytochrome P450 2D6 (CYP2D6) enzyme. Genetic polymorphisms in CYP2D6 lead to significant inter-individual variability in analgesic response and toxicity risk. "Ultra-rapid metabolizers" are at high risk for opioid toxicity, including life-threatening respiratory depression, a fact highlighted in a specific FDA Black Box Warning that has led to contraindications in pediatric populations.

Reflecting its complex risk profile, tramadol carries several significant warnings. Beyond the risks of addiction, abuse, and misuse common to all opioids, it poses a dose-dependent risk of seizures and serotonin syndrome, particularly when co-administered with other serotonergic agents or drugs that lower the seizure threshold. Initially approved in the United States in 1995 as a non-controlled substance, accumulating evidence of its abuse potential led the Drug Enforcement Administration (DEA) to classify tramadol as a Schedule IV controlled substance in 2014. This report provides an exhaustive analysis of tramadol's chemistry, pharmacology, clinical applications, dosing, safety profile, and regulatory history, serving as a definitive reference for healthcare professionals, researchers, and regulatory experts.

Chemical Identity and Physicochemical Properties

A. Identification and Nomenclature

Tramadol is a well-characterized small molecule drug with established identifiers used in scientific, regulatory, and clinical contexts. Its primary name is Tramadol, with the Latin form being Tramadolum.[1] It is cataloged in major chemical and pharmacological databases under specific codes:

• DrugBank ID: DB00193 [1]
• CAS Number: 27203-92-5 [2]

The CAS number 27203-92-5 specifically refers to the racemic, cis-isomer of the compound, which is the pharmacologically active form used in medicinal products.[2] The drug is chemically defined as (±)cis-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, often used as its hydrochloride salt.[5]

The molecular formula for the base compound is C16​H25​NO2​, with a corresponding molecular weight of 263.38 g/mol.[2] The hydrochloride salt, which is the common pharmaceutical form, has a molecular weight of 299.8 g/mol.[5] Tramadol is known by numerous synonyms and brand names, including Ultram, Conzip, Ryzolt, and Tramal, reflecting its global market presence.[1]

B. Stereochemistry and Structural Analysis

Tramadol is a synthetic 4-phenyl-piperidine analogue of codeine and is structurally related to both codeine and morphine.[1] Its structure contains two stereogenic centers on the cyclohexanol ring, located at carbons 1 and 2. This allows for the existence of four distinct stereoisomers.[9]

The pharmaceutical product is not a single enantiomer but a specific racemic mixture (a 1:1 ratio) of the (+)-(1R,2R) and (-)-(1S,2S) enantiomers.[7] This formulation is a deliberate pharmacological strategy, as extensive research in both animal and human models has demonstrated that the racemate possesses greater analgesic activity than either of its constituent enantiomers when administered alone.[8] This supra-additive or synergistic effect is a cornerstone of tramadol's unique clinical profile and is due to the complementary mechanisms of action of the two isomers, which will be detailed in the pharmacology section.

The chemical synthesis of tramadol, as first described by the originator Grünenthal GmbH, primarily yields the cis-diastereomeric racemate. This desired product is then isolated from the minor amounts of the trans-diastereomeric racemate that are also formed during the reaction, typically through recrystallization of the hydrochloride salt.[4]

C. Physicochemical Properties

Tramadol hydrochloride is a white to off-white, crystalline, and odorless powder with a distinctly bitter taste.[5] In its base form, it has been described as a light yellow oil.[4] It exhibits high solubility in water and ethanol, which facilitates its formulation into various dosage forms.[5] The compound's pKa is 9.41, and its n-octanol/water partition coefficient (logP) is 1.35 at pH 7, indicating moderate lipophilicity that allows it to cross biological membranes, including the blood-brain barrier.[5]

Table 1: Physicochemical Properties of Tramadol

Property	Value	Source Snippet(s)
CAS Number	27203-92-5	2
Molecular Formula	C16​H25​NO2​	2
Molecular Weight	263.38 g/mol (base); 299.8 g/mol (HCl salt)	5
Appearance	White, crystalline, odorless powder (HCl salt)	5
Melting Point	178-181 °C	6
pKa	9.41	5
LogP	1.35 (at pH 7)	5
Solubility	Readily soluble in water and ethanol	5

D. The "Natural Origin" Controversy

A noteworthy episode in the scientific history of tramadol involves claims of its natural origin. In 2013, researchers reported finding high concentrations of tramadol (over 1%) in the root bark of the African pin cushion tree, Nauclea latifolia.[9] This finding was remarkable, as tramadol was believed to be an exclusively synthetic compound. However, subsequent investigations cast significant doubt on this conclusion.

In 2014, another research group proposed an alternative hypothesis: anthropogenic contamination. They presented evidence that the tramadol detected in the tree roots was the result of widespread use of the synthetic drug in local human populations and its administration to cattle by farmers. They argued that the drug and its mammalian metabolites were excreted into the environment, contaminating the soil and subsequently being absorbed by the trees.[9] This hypothesis was supported by the observation that tramadol and its metabolites were found in tree roots in northern Cameroon, where the drug was in common use, but were absent in roots from southern regions where it was not.[9]

The controversy was largely settled in 2016 when a follow-up study employed radiocarbon analysis. This technique can distinguish between carbon derived from modern biological sources (plants) and carbon from petrochemicals (the source for synthetic drugs). The analysis definitively showed that the carbon in the tramadol from the N. latifolia roots was of synthetic origin, confirming the contamination hypothesis.[9] This episode serves as a modern cautionary tale in pharmacognosy, highlighting the critical importance of rigorous scientific validation and the potential for environmental contamination by widely used pharmaceuticals to confound natural product research.

Pharmacology and Mechanism of Action

A. Overview of Dual-Action Analgesia

Tramadol is a centrally-acting synthetic analgesic whose clinical efficacy stems from a complex and unique dual mechanism of action.[1] Unlike traditional opioids that rely almost exclusively on µ-opioid receptor agonism, tramadol's therapeutic effect is the result of at least two complementary and synergistic pathways: weak binding to µ-opioid receptors and the inhibition of monoamine reuptake (serotonin and norepinephrine).[5] This multimodal approach to pain modulation allows tramadol to be effective against various pain types, including nociceptive, inflammatory, and neuropathic pain.[1]

Due to its distinct profile and good general tolerability, it is considered a Step 2 option on the World Health Organization's (WHO) three-step pain ladder, positioned for pain that is not controlled by non-opioid analgesics alone but does not yet require strong opioids.[1] Its analgesic potency is estimated to be approximately one-tenth that of morphine.[1]

B. Mechanism 1: Opioid Receptor Agonism

The first component of tramadol's action involves the opioid system. Both the parent drug and, more importantly, its primary active metabolite, O-desmethyltramadol (M1), are agonists of the µ-opioid receptor.[1] However, their affinities for this receptor differ dramatically. The parent compound, tramadol itself, exhibits a very low affinity for the µ-opioid receptor, approximately 6,000 times lower than that of morphine.[5]

The majority of the opioid-mediated analgesia is attributable to the M1 metabolite. Following hepatic metabolism, M1 is formed, which has a 200-fold higher binding affinity for the µ-opioid receptor compared to the parent drug.[5] In animal models, M1 has been shown to be up to six times more potent than tramadol in producing analgesia.[5] This metabolic conversion is therefore a critical determinant of the drug's opioid effect. The fact that tramadol-induced analgesia is only partially reversed by the opioid antagonist naloxone was a key early finding that pointed toward the existence of a significant non-opioid mechanism of action.[5]

C. Mechanism 2: Monoamine Reuptake Inhibition

The second, non-opioid mechanism of action is the inhibition of the reuptake of the monoamine neurotransmitters norepinephrine (NE) and serotonin (5-hydroxytryptamine, 5-HT) within the central nervous system.[1] This action is analogous to that of Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) antidepressants such as duloxetine and venlafaxine.[7]

By blocking their reuptake, tramadol increases the synaptic concentrations of NE and 5-HT. This enhances the activity of the descending inhibitory pain pathways that originate in the brainstem and project down to the spinal cord.[8] These pathways act as a "braking system" on nociceptive signals, effectively blocking the transmission of pain impulses from the periphery to the brain at the spinal level. This monoaminergic mechanism is thought to be particularly important for tramadol's efficacy in treating neuropathic pain, a condition often poorly responsive to traditional opioids.[7]

D. Enantiomer-Specific Contributions to the Dual Mechanism

The use of tramadol as a racemic mixture is fundamental to its dual-action profile, as the two enantiomers possess distinct and complementary pharmacological activities that work in synergy.[8]

• (+)-Tramadol: This enantiomer is a more potent µ-opioid receptor agonist and also preferentially inhibits the reuptake of serotonin. Furthermore, its metabolite, (+)-O-desmethyltramadol (M1), is the primary driver of the potent opioid effect.[9]
• (-)-Tramadol: This enantiomer is a much weaker opioid agonist but is the primary inhibitor of norepinephrine reuptake.[8]

This division of labor allows the racemate to engage all three analgesic pathways—µ-opioid, serotonergic, and noradrenergic—simultaneously. This multi-pronged attack on pain signaling pathways is what underlies the observation that the racemic mixture is more effective than either enantiomer alone.[8]

Table 2: Pharmacological Activity of Tramadol Enantiomers and M1 Metabolite

Component	µ-Opioid Receptor Affinity	Norepinephrine Reuptake Inhibition	Serotonin Reuptake Inhibition
(±) Tramadol (Racemate)	++	+	+
(+) Tramadol	+++	+	++
(-) Tramadol	+	++	+
(+) M1 Metabolite	++++
Morphine (for comparison)	+++++
Source: Adapted from Benzon H. Practical Management of Pain. 5th ed. Mosby, St. Louis, 2014, as cited in.12 The number of '+' signs indicates relative affinity/activity.

E. Other Pharmacodynamic Effects

Beyond its primary analgesic actions, tramadol exerts several other pharmacodynamic effects, many of which are characteristic of its dual-class nature.

• Antitussive Effects: Like other opioids, tramadol suppresses the cough reflex through a direct effect on the cough center in the medulla. This antitussive effect may occur at doses lower than those typically required for analgesia.[1]
• Ocular Effects: Tramadol causes miosis (constriction of the pupils), a classic sign of opioid activity. This effect occurs even in total darkness.[1]
• Gastrointestinal Effects: Tramadol impacts the GI tract in a manner typical of opioids. It reduces motility and increases smooth muscle tone in the stomach and duodenum, delaying gastric emptying. In the colon, it decreases propulsive peristaltic waves while increasing tone, which can lead to spasms and constipation. It can also cause a reduction in gastric, biliary, and pancreatic secretions and spasm of the Sphincter of Oddi.[1]
• Anxiolytic and Antidepressant Effects: A direct consequence of its SNRI activity, tramadol can produce anxiolytic (anti-anxiety) and antidepressant effects. This can be a clinically advantageous side effect in patients who suffer from pain with comorbid depression or anxiety, which are common comorbidities.[1]

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of tramadol describes its journey through the body, which is characterized by rapid absorption, extensive distribution, complex metabolism heavily influenced by genetic factors, and primarily renal elimination.

A. Absorption

Following oral administration, tramadol is rapidly and almost completely absorbed from the gastrointestinal tract.[10] The mean absolute bioavailability of a 100 mg immediate-release (IR) oral dose is approximately 75%, with the remaining fraction undergoing first-pass metabolism.[5]

For IR formulations, peak plasma concentrations (Cmax​) of the parent drug are achieved in approximately 2 hours, while the active M1 metabolite reaches its Cmax​ at around 3 hours.[5] With regular four-times-daily dosing, steady-state plasma concentrations of both tramadol and M1 are attained within two days.[11]

Extended-release (ER) formulations are designed to provide prolonged analgesia by releasing the drug over a 12- or 24-hour period. This results in a slower attainment of peak concentrations (e.g., a Tmax​ of 4.9 hours for one formulation) and more stable plasma levels throughout the dosing interval, which can improve tolerability by avoiding the sharp peaks and troughs seen with IR formulations.[10]

B. Distribution

Once absorbed, tramadol is rapidly distributed throughout the body tissues.[10] It has a large volume of distribution (

Vd​), measured at 2.6 L/kg in males and 2.9 L/kg in females.[11] A

Vd​ significantly larger than total body water indicates extensive sequestration of the drug in extravascular tissues, including the central nervous system, its primary site of action.

Plasma protein binding is low, at approximately 20%.[10] This means a large fraction (about 80%) of the drug in circulation is unbound and pharmacologically active, free to distribute to tissues and interact with receptors. This low protein binding also contributes to its extensive distribution. Tramadol is known to cross the placental barrier and is also excreted in small quantities into breast milk.[12]

C. Metabolism: The Central Role of Cytochrome P450

Tramadol undergoes extensive metabolism in the liver, with only about 30% of an oral dose being excreted as unchanged drug.[5] The metabolic processes involve a number of pathways, but the most significant are N- and O-demethylation, which are mediated by the cytochrome P450 (CYP) enzyme system, followed by conjugation reactions (glucuronidation or sulfation) to form more water-soluble compounds for excretion.[5]

The two primary demethylation pathways are catalyzed by different CYP isoenzymes and produce metabolites with different activities:

• O-demethylation: This pathway converts tramadol to O-desmethyltramadol (M1), the principal pharmacologically active metabolite responsible for most of the drug's opioid effect. This critical conversion is catalyzed by the CYP2D6 isoenzyme.[4]
• N-demethylation: This pathway converts tramadol to N-desmethyltramadol (M2), a largely inactive metabolite. This reaction is catalyzed by CYP3A4 and CYP2B6.[10]

This reliance on specific CYP enzymes, particularly CYP2D6, makes tramadol susceptible to both genetic variations and drug-drug interactions that can alter its metabolic fate and, consequently, its clinical effect.

D. The Impact of CYP2D6 Genetic Polymorphism

The gene encoding the CYP2D6 enzyme is highly polymorphic, meaning numerous genetic variants exist within the human population. These variants result in differing levels of enzyme activity, which directly and profoundly impacts tramadol's pharmacokinetics and clinical outcomes.[8] This creates a direct link between a patient's genetic makeup and their response to the drug. The population can be broadly categorized based on their CYP2D6 phenotype:

• Poor Metabolizers (PMs): These individuals (comprising about 7% of the Caucasian population) possess two non-functional CYP2D6 alleles and have significantly reduced or absent enzyme activity. When given tramadol, they are unable to efficiently convert it to the active M1 metabolite. This results in approximately 20% higher plasma concentrations of the parent drug (tramadol) and 40% lower concentrations of the active M1 metabolite. Consequently, PMs often experience diminished analgesic relief from tramadol because they cannot generate sufficient levels of the potent opioid agonist.[5]
• Extensive Metabolizers (EMs): This is the "normal" phenotype, possessing at least one functional CYP2D6 allele. They metabolize tramadol as expected, achieving a therapeutic balance between the parent drug and the M1 metabolite.
• Ultra-Rapid Metabolizers (URMs): These individuals carry multiple copies of the functional CYP2D6 gene, leading to markedly increased enzyme activity. When they take tramadol, they convert it to the M1 metabolite much more rapidly and completely than EMs. This leads to the formation of unexpectedly high and potentially toxic concentrations of the potent M1 metabolite, even at standard therapeutic doses. URMs are therefore at a significantly increased risk for opioid toxicity, including severe and life-threatening respiratory depression. This risk is the basis for a key FDA Black Box Warning and contraindications for tramadol use in children.[15]

E. Elimination

Tramadol and its metabolites are eliminated from the body primarily through the kidneys.[10] Approximately 90% of an administered dose is excreted in the urine, with about 30% as unchanged tramadol and 60% as metabolites.[5] The remaining 10% is excreted in the feces.[12]

The mean terminal elimination half-life (t1/2​) of racemic tramadol is approximately 6.3 hours, while the active M1 metabolite has a slightly longer half-life of 7.4 hours.[5] The extensive tissue distribution and hepatic metabolism mean that only a very small fraction of the drug is removed by hemodialysis (approximately 7%), rendering it an ineffective method for managing overdose.[17]

Table 3: Key Pharmacokinetic Parameters of Tramadol

Parameter	Value	Source Snippet(s)
Absolute Bioavailability	~75% (oral)	5
Time to Peak Plasma Conc. (Tmax​)	~2 hours (Tramadol); ~3 hours (M1 metabolite)	5
Volume of Distribution (Vd​)	2.6 L/kg (males); 2.9 L/kg (females)	11
Plasma Protein Binding	~20%	10
Elimination Half-Life (t1/2​)	~6.3 hours (Tramadol); ~7.4 hours (M1 metabolite)	5
Primary Metabolism	Hepatic O- and N-demethylation (CYP2D6, CYP3A4/2B6)	5
Primary Excretion	Renal (~90%)	10

Clinical Applications

A. FDA-Approved Indications

Tramadol is officially indicated by the U.S. Food and Drug Administration (FDA) for the management of pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments (e.g., non-opioid analgesics) are inadequate.[11]

This indication has important limitations. Due to the established risks of addiction, abuse, and misuse, the FDA advises that tramadol should be reserved for patients for whom other options have failed or are not tolerated.[18] The different formulations are intended for different pain scenarios:

• Immediate-Release (IR) Formulations (tablets, oral solution): Intended for the management of acute pain where the use of an opioid is appropriate.[20] These are typically used for short-term treatment (e.g., less than a week) and are not intended for "as-needed" (prn) use over long periods.[11]
• Extended-Release (ER) Formulations (capsules, tablets): Indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.[15] These formulations are not for acute or "as-needed" pain relief.[15]

B. Off-Label and Investigational Uses

Beyond its primary indication for pain, tramadol has been used and investigated for several off-label conditions, primarily leveraging its unique SNRI properties.

• Premature Ejaculation: Tramadol has been used off-label to treat premature ejaculation that is refractory to other therapies.[1] The American Urological Association (AUA) guidelines suggest that low-dose, on-demand tramadol (e.g., 25 mg to 50 mg taken before intercourse) may be considered for patients who have not responded to first-line treatments.[11]
• Restless Legs Syndrome (RLS): There is some evidence for its use in treating RLS that is refractory to standard medications.[11]
• Other Investigational Uses: Tramadol has also been investigated for diabetic neuropathy, postherpetic neuralgia, and as an adjunct to local anesthesia.[9] Its SNRI activity also confers anxiolytic, antidepressant, and anti-shivering effects, which can be beneficial in patients with pain where these are common comorbidities.[1]

C. Efficacy in Diverse Pain Conditions

The dual mechanism of action makes tramadol effective across a broad spectrum of pain states, a versatility not always seen with traditional opioids. Clinical evidence has demonstrated its efficacy in:

• Post-operative Pain: Provides pain relief comparable to pethidine and is a common option for managing pain after surgery.[1]
• Neuropathic Pain: Its ability to inhibit norepinephrine and serotonin reuptake makes it particularly useful for neuropathic pain, a condition often driven by central sensitization.[1]
• Musculoskeletal and Chronic Pain: It is used for chronic lower back pain, osteoarthritis, and fibromyalgia.[1]
• Other Pain States: It has also been used to manage pain associated with cancer, labor, and renal or biliary colic.[1]

Dosage and Administration

The administration of tramadol requires careful individualization of dosage based on the patient's severity of pain, prior analgesic experience, response to treatment, and risk factors for abuse and misuse. The goal is to use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.[19]

A. Available Formulations and Strengths

Tramadol is available in multiple oral formulations to accommodate different clinical needs [11]:

• Immediate-Release (IR) Tablets: Strengths of 25 mg, 50 mg, and 100 mg.[17]
• Extended-Release (ER) Tablets/Capsules: Designed for once-daily (24-hour) or twice-daily (12-hour) dosing. Strengths include 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 300 mg, and 400 mg.[13]
• Oral Solution: Typically 5 mg/mL, allowing for flexible dose titration.[17]
• Orodispersible (dissolvable) Tablets: 50 mg strength for patients who have difficulty swallowing.[13]
• Injectable Solution: For parenteral (IV/IM) administration, typically used in a hospital setting.[9]

A critical administration instruction for all ER formulations is that the tablets or capsules must be swallowed whole and must never be crushed, chewed, split, or dissolved. Doing so would defeat the slow-release mechanism, causing a rapid release of the entire dose ("dose dumping"), which could lead to a potentially fatal overdose.[11]

B. Dosing Regimens

For Adults (17 years and older)

• Acute Pain (IR Formulations): The usual starting dose is 50 mg to 100 mg orally every 4 to 6 hours as needed for pain. The maximum daily dose should not exceed 400 mg.[11]
• For Patients Not Requiring Rapid Onset (Slow Titration): To improve tolerability and reduce the incidence of side effects like nausea and dizziness, a slower titration is recommended. Start with 25 mg once daily and increase in 25 mg increments every 3 days to reach a dose of 100 mg/day (25 mg four times a day). Thereafter, the dose can be increased by 50 mg every 3 days as tolerated, up to the maximum of 400 mg/day.[18]
• Chronic Pain (ER Formulations): For opioid-naïve patients, treatment is typically initiated at 100 mg once daily. The dose can then be titrated upwards in 100 mg increments every 5 days to an effective dose that minimizes adverse effects. The maximum daily dose for ER formulations is typically 300 mg.[21]
• Conversion from IR to ER: Patients converting from IR tramadol should have their total 24-hour IR dose calculated. The ER therapy is then initiated with a total daily dose rounded down to the nearest 100 mg increment, administered once daily.[17]

C. Dosing in Specific Populations

• Geriatric Patients (Over 65 years): Should be initiated at the lower end of the dosing range. For patients over 75 years of age, the maximum recommended daily dose for IR formulations is 300 mg due to potential for prolonged elimination.[11] Close monitoring for CNS and respiratory depression is essential.[24]
• Renal Impairment (Severe, CrCl <30 mL/min):
• IR Formulations: The dosing interval should be increased to every 12 hours, and the maximum daily dose limited to 200 mg.[17]
• ER Formulations: Use is not recommended.[17]
• Hepatic Impairment (Severe, Cirrhosis/Child-Pugh Class C):
• IR Formulations: The recommended dose is 50 mg orally every 12 hours.[18]
• ER Formulations: Use is not recommended.[17]
• Pediatric Patients: Tramadol is contraindicated in children younger than 12 years of age and for postoperative management in children younger than 18 years following tonsillectomy and/or adenoidectomy.[11] ER formulations are not recommended in any pediatric patients.[11]

Adverse Effects

The adverse effect profile of tramadol is a composite of effects typical of both opioid analgesics and SNRI antidepressants. The most commonly reported adverse drug reactions are dose-dependent and include nausea, dizziness, constipation, somnolence (drowsiness), vomiting, pruritus (itching), and headache.[1]

A. Common Side Effects

• Central Nervous System (CNS): Dizziness, somnolence, headache, vertigo, nervousness, anxiety, changes in mood, and uncontrollable shaking (tremor) are frequently observed.[1] Drowsiness and impaired coordination can affect the ability to drive or operate machinery.[20]
• Gastrointestinal (GI): Nausea, vomiting, constipation, dry mouth, and indigestion are very common.[1] Constipation is a hallmark opioid-induced side effect resulting from decreased GI motility.[1]
• Dermatological: Sweating and pruritus are common.[1]

B. Serious Adverse Effects

• Respiratory Depression: As an opioid agonist, tramadol can cause serious, life-threatening, or fatal respiratory depression. This risk is highest during the first 24 to 72 hours of treatment initiation and following any dose increase.[20]
• Seizures: Tramadol lowers the seizure threshold and can induce convulsions, even at recommended therapeutic doses. The risk is significantly increased at higher doses, in patients with a history of epilepsy, or with concomitant use of other drugs that also lower the seizure threshold (e.g., certain antidepressants, antipsychotics).[1]
• Serotonin Syndrome: Due to its inhibition of serotonin reuptake, tramadol can cause serotonin syndrome, a potentially life-threatening condition resulting from excessive serotonergic activity in the CNS. The risk is greatest when tramadol is used concurrently with other serotonergic drugs, such as SSRIs, SNRIs, triptans, and MAOIs.[1] Symptoms can include agitation, confusion, rapid heart rate, hypertension, hyperthermia, tremor, hyperreflexia, and clonus.[12]
• Addiction, Dependence, and Withdrawal: Prolonged use of tramadol can lead to physical dependence and addiction (opioid use disorder). Abrupt discontinuation can precipitate a withdrawal syndrome.[1]
• Anaphylaxis and Hypersensitivity: Serious allergic reactions, including anaphylaxis, have been reported.[15]
• Hypotension: Tramadol can cause severe hypotension, including orthostatic hypotension and syncope (fainting), particularly upon standing up from a lying position.[19]
• Adrenal Insufficiency: Cases of adrenal insufficiency have been reported with opioid use. If diagnosed, treatment involves corticosteroid replacement and weaning the patient off the opioid.[19]
• Decreased Fertility: Tramadol use may be associated with decreased fertility in both men and women.[20]

Warnings, Precautions, and Contraindications

The use of tramadol is governed by a stringent set of warnings, precautions, and contraindications, encapsulated in a prominent FDA Black Box Warning. This reflects a complex risk profile that requires careful patient selection and monitoring.

A. FDA Black Box Warning Analysis

The FDA mandates its strongest warning, a "boxed warning," for tramadol, highlighting several potentially fatal risks. The evolution of this warning reflects a growing understanding of the drug's dangers, moving from general opioid risks to highly specific, mechanism-based concerns.[16]

1. Addiction, Abuse, and Misuse: Tramadol exposes patients to the risks of opioid use disorder, which can lead to overdose and death. The FDA requires a thorough risk assessment for addiction, abuse, and misuse before prescribing, as well as regular monitoring throughout therapy. This warning was strengthened for all opioids in 2016 in response to the national opioid crisis.[16]
2. Life-Threatening Respiratory Depression: This is the most serious acute risk associated with tramadol. It can occur at any time but is most likely during treatment initiation (the first 24-72 hours) and after any dosage increase. Close monitoring is critical. The risk is significantly elevated in elderly, cachectic (severely weakened), or debilitated patients, and in those with pre-existing pulmonary conditions like COPD or asthma.[16]
3. Accidental Ingestion: Accidental ingestion of even a single dose of tramadol, particularly by a child, can result in a fatal overdose due to respiratory depression.[16] This underscores the need for safe storage of the medication.
4. Neonatal Opioid Withdrawal Syndrome (NOWS): Prolonged use of tramadol during pregnancy can lead to the development of physical dependence in the fetus. Upon birth, the infant may suffer from NOWS, a life-threatening condition requiring specialized medical care. Symptoms in the newborn include irritability, hyperactivity, high-pitched crying, tremors, vomiting, diarrhea, and failure to gain weight.[16]
5. Risks from Concomitant Use with Benzodiazepines or other CNS Depressants: The co-administration of tramadol with other CNS depressants—including benzodiazepines, other opioids, sedatives, tranquilizers, and alcohol—can result in profound sedation, respiratory depression, coma, and death. This combination should be reserved only for patients for whom alternative treatment options are inadequate, using the lowest effective doses for the shortest possible duration.[16]
6. Ultra-Rapid Metabolism of Tramadol and Other Risk Factors for Life-threatening Respiratory Depression in Children: This highly specific warning is a direct consequence of pharmacogenomic discoveries. It addresses the danger posed to individuals who are CYP2D6 ultra-rapid metabolizers (URMs). These patients convert tramadol to its highly potent M1 metabolite far more rapidly and completely than the general population, leading to dangerously high, toxic levels of M1 and an increased risk of severe opioid toxicity, even at standard doses. This finding has been directly linked to reports of death and life-threatening respiratory depression in children treated with tramadol, particularly after tonsillectomy or adenoidectomy, leading to specific contraindications in the pediatric population.[15]

B. Contraindications

Based on the risks outlined above, tramadol is strictly contraindicated in several populations:

• Pediatric Population:
• In all children younger than 12 years of age.[11]
• For post-operative pain management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy.[11] This specific contraindication targets a "perfect storm" scenario where children, who may have underlying obstructive sleep apnea and are inherently more sensitive to opioids, could also be CYP2D6 URMs, creating an unacceptable risk of fatal respiratory depression.
• Respiratory Conditions: In patients with significant respiratory depression, acute or severe bronchial asthma (in an unmonitored setting or without resuscitative equipment).[18]
• Gastrointestinal Conditions: In patients with known or suspected gastrointestinal obstruction, including paralytic ileus.[18]
• Hypersensitivity: In patients with a known history of hypersensitivity or anaphylactic reactions to tramadol, other opioids, or any component of the formulation.[18]
• Monoamine Oxidase Inhibitor (MAOI) Use: Concurrent use with MAOIs, or use within 14 days of discontinuing an MAOI, is contraindicated due to the high risk of precipitating serotonin syndrome.[18]

C. Precautions and High-Risk Populations

• Seizure Risk: Tramadol should be used with extreme caution in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, metabolic disorders, CNS infections, alcohol/drug withdrawal). The risk is dose-dependent and is exacerbated by co-administration of other drugs that lower the seizure threshold.[1]
• Suicide Risk: Tramadol should not be prescribed for patients who are suicidal or addiction-prone. Caution is advised when prescribing to patients with a history of emotional disturbance or depression, those who abuse alcohol, or those taking other CNS-active drugs like antidepressants or tranquilizers.[9]
• Head Injury and Increased Intracranial Pressure: Opioids can elevate cerebrospinal fluid pressure and obscure the clinical course of patients with head injuries. Tramadol's potential to reduce respiratory drive can lead to carbon dioxide retention, which further increases intracranial pressure. Its use should be avoided in patients with impaired consciousness or coma.[11]
• Renal and Hepatic Impairment: Dosage adjustments are necessary for patients with severe renal or hepatic impairment. Extended-release formulations are generally not recommended in these populations due to the lack of dosing flexibility and potential for drug accumulation.[17]

Drug Interactions

Tramadol is subject to numerous clinically significant drug interactions that can alter its efficacy and increase the risk of severe adverse events. These interactions stem from its complex metabolism via CYP enzymes and its dual pharmacodynamic actions on opioid and monoaminergic systems. There are over 700 drugs known to interact with tramadol, with over 300 classified as major interactions.[32]

A. Pharmacokinetic Interactions (CYP450-Mediated)

• CYP2D6 Inhibitors: Co-administration of tramadol with strong inhibitors of CYP2D6 (e.g., bupropion, fluoxetine, paroxetine, quinidine) can block the metabolic conversion of tramadol to its active M1 metabolite. This leads to increased plasma concentrations of the parent drug (tramadol) and decreased concentrations of the potent M1 metabolite. The clinical result can be reduced analgesic efficacy and potentially increased risk of side effects associated with the parent compound, such as seizures and serotonin syndrome.[5]
• CYP3A4 Inhibitors: Co-administration with strong inhibitors of CYP3A4 (e.g., ketoconazole, ritonavir, clarithromycin) can inhibit the clearance of both tramadol and its M1 metabolite. This can lead to elevated levels of both compounds, increasing the risk of opioid toxicity, including potentially fatal respiratory depression.[4]
• CYP3A4 Inducers: Co-administration with strong inducers of CYP3A4 (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort) can accelerate the metabolism of tramadol, leading to lower plasma concentrations of the parent drug. This may result in decreased analgesic efficacy and could precipitate withdrawal symptoms in patients who are physically dependent on the drug.[30]

B. Pharmacodynamic Interactions

• Serotonergic Drugs: This is one of the most critical interactions. Concurrent use of tramadol with other drugs that increase serotonin levels significantly increases the risk of serotonin syndrome. This includes:
• Selective Serotonin Reuptake Inhibitors (SSRIs) like sertraline (Zoloft) and escitalopram (Lexapro).[14]
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) like duloxetine (Cymbalta) and venlafaxine.[14]
• Tricyclic Antidepressants (TCAs) like amitriptyline.[31]
• Monoamine Oxidase Inhibitors (MAOIs), which are contraindicated.[18]
• Triptans (migraine medications) like sumatriptan.[31]
• Other opioids like tapentadol and fentanyl.[14]
• The herbal supplement St. John's Wort.[27]
• CNS Depressants: As highlighted in the Black Box Warning, combining tramadol with any other CNS depressant can lead to additive effects, resulting in profound sedation, respiratory depression, hypotension, coma, and death. This class includes:
• Benzodiazepines like alprazolam (Xanax) and diazepam (Valium).[18]
• Alcohol, which is highly dangerous to mix with tramadol.[27]
• Other Opioids.[31]
• Barbiturates like phenobarbital.[31]
• Sleep aids like zolpidem (Ambien) and diphenhydramine (Benadryl).[27]
• Muscle relaxants like cyclobenzaprine (Flexeril) and methocarbamol (Robaxin).[14]
• Drugs that Lower the Seizure Threshold: Tramadol itself lowers the seizure threshold. When combined with other medications that do the same, the risk of seizures is substantially increased. Such drugs include:
• Bupropion (Wellbutrin).[31]
• Antidepressants (SSRIs, TCAs).[31]
• Antipsychotics like clozapine and olanzapine.[27]
• Other opioids.[15]
• Warfarin: Tramadol may enhance the anticoagulant effect of warfarin, leading to an increased risk of bleeding. Patients on this combination require careful monitoring of their INR (International Normalized Ratio).[27]
• Diuretics: Tramadol can diminish the efficacy of diuretics by stimulating the release of antidiuretic hormone (ADH), which promotes fluid retention. This can lead to reduced diuretic effect and potential complications like edema and increased blood pressure.[27]

Toxicity and Overdose Management

An overdose of tramadol is a medical emergency that can be life-threatening. While tramadol is often perceived as a "weaker" opioid, overdose is possible and presents a complex clinical picture due to the drug's dual mechanism of action.[33] Fatalities are more common when tramadol is ingested as part of a polysubstance overdose, particularly with other CNS depressants like alcohol or benzodiazepines.[33]

A. Signs and Symptoms of Overdose

Tramadol toxicity manifests with a constellation of symptoms that includes a classic opioid toxidrome combined with unique neurological and cardiovascular effects. The amount of tramadol required to cause an overdose varies significantly between individuals, depending on factors like tolerance, body weight, and CYP2D6 metabolic status.[34]

Key signs and symptoms of tramadol overdose include:

• CNS Depression: Ranging from somnolence and extreme drowsiness to unresponsiveness and coma.[9]
• Respiratory Depression: Slowed, shallow, or absent breathing is the most life-threatening symptom of opioid overdose and can lead to anoxic brain injury and death.[20]
• Seizures: A hallmark feature of tramadol toxicity that distinguishes it from most other opioids. Seizures are often generalized tonic-clonic and can occur even at therapeutic doses, but the risk is much higher in overdose settings.[9]
• Serotonin Syndrome: In cases of significant overdose or co-ingestion of other serotonergic agents, patients may exhibit symptoms of serotonin syndrome, including agitation, confusion, hyperthermia, tachycardia, hypertension, hyperreflexia, and clonus.[35]
• Cardiovascular Effects: Tachycardia (rapid heart rate) and mild hypertension are common. However, severe complications can occur, including QRS widening and QTc prolongation on an ECG, arrhythmias, and, in extreme cases, cardiopulmonary arrest.[9]
• Other Opioid Signs: Miosis (pinpoint pupils), muscle weakness or flaccidity, and cold, clammy skin are also characteristic.[20]

B. Overdose Management and Treatment

Management of a suspected tramadol overdose requires immediate medical intervention. If an overdose is suspected, emergency services (911) should be called immediately.[36] Treatment is primarily supportive and aimed at managing life-threatening complications.

1. Airway, Breathing, and Circulation (ABCs): The first priority is to establish and maintain a patent airway and support respiration and circulation. Supplemental oxygen and, if necessary, mechanical ventilation are critical for managing respiratory depression.[36]
2. Naloxone Administration: Naloxone, an opioid antagonist, is the antidote for opioid-induced respiratory depression. It can be administered to reverse this life-threatening effect. However, its role in tramadol overdose is complex. While it can reverse respiratory depression, naloxone does not reverse tramadol-induced seizures and may, in fact, increase the risk of seizures.[29] Therefore, it must be used cautiously. Because naloxone has a shorter half-life than tramadol, repeated doses may be necessary, and continuous monitoring is required even after an initial response.[36]
3. Seizure Management: Tramadol-induced seizures are typically managed with intravenous benzodiazepines, such as lorazepam or diazepam. Supportive care to prevent injury during a seizure is also important.[33]
4. Serotonin Syndrome Management: If serotonin syndrome is present, treatment involves discontinuing all serotonergic agents, providing aggressive supportive care (including external cooling for hyperthermia), and administering benzodiazepines for agitation and muscle rigidity. In severe cases, a serotonin antagonist like cyproheptadine may be considered.[12]
5. Gastrointestinal Decontamination: The use of activated charcoal may be considered if the patient presents within one hour of a significant ingestion, but its use is controversial and should only be done after the airway is secured.
6. Supportive Care: Continuous monitoring of vital signs, cardiac rhythm (ECG), and mental status is essential. Intravenous fluids may be needed to manage hypotension.[36] As noted previously, hemodialysis is not effective in removing tramadol from the body.[17]

Dependence, Abuse, and Withdrawal

Like other opioid analgesics, tramadol carries a significant risk of physical dependence, psychological addiction (opioid use disorder), and a subsequent withdrawal syndrome upon cessation. Its abuse potential was initially underestimated, leading to its initial marketing as a non-controlled substance, a status that was later revised based on extensive post-marketing evidence of misuse.[38]

A. Physical Dependence and Addiction

Physical dependence is a state of neuroadaptation that occurs with prolonged use, where the body becomes reliant on the drug to function normally. This is an expected physiological response and is not synonymous with addiction. If the drug is stopped abruptly, a withdrawal syndrome will occur.[1]

Addiction, or opioid use disorder, is a chronic, relapsing brain disease characterized by compulsive drug-seeking and use despite harmful consequences. It involves complex changes in brain circuits related to reward, stress, and self-control.[38] The risk of developing addiction is higher in patients with a personal or family history of substance abuse or mental illness.[38]

B. Tramadol Withdrawal Syndrome

The withdrawal syndrome from tramadol is unique because of the drug's dual mechanism of action. Most patients experience a withdrawal profile typical of other opioids, but a minority experience an atypical syndrome related to the discontinuation of its SNRI effects.[38]

Typical Opioid Withdrawal Syndrome (~90% of cases)

This syndrome is intensely uncomfortable but rarely life-threatening. Symptoms are often described as being "flu-like" and include [38]:

• Gastrointestinal: Nausea, vomiting, diarrhea, stomach cramps.
• Musculoskeletal: Muscle aches and pains, body aches.
• Autonomic: Sweating, chills, piloerection (goosebumps), runny nose (rhinorrhea), teary eyes (lacrimation), yawning.
• Psychological: Anxiety, restlessness, irritability, insomnia, intense drug cravings.

Atypical Withdrawal Syndrome (~10% of cases)

This second type of withdrawal is associated with the abrupt cessation of serotonin and norepinephrine reuptake inhibition and is not seen with classic opioids. It can be more psychologically distressing and includes symptoms such as [38]:

• Psychiatric: Extreme anxiety, panic attacks, paranoia, confusion, hallucinations (auditory or visual).
• Neurological: Paresthesias (numbness, tingling, or a sensation of insects crawling on the skin), tremors.

C. Withdrawal Timeline and Management

The onset and duration of withdrawal can vary based on the dose and duration of use, the specific formulation (IR vs. ER), and individual patient factors.[42]

• Early Stage (6-24 hours after last dose): Symptoms begin to emerge, including anxiety, muscle aches, and insomnia.[39]
• Peak Stage (24-72 hours after last dose): Symptoms reach their maximum intensity. Both physical (flu-like) and psychological symptoms are most severe during this period.[41]
• Subsides (4-7 days after last dose): Acute physical symptoms begin to gradually decrease, though psychological symptoms like anxiety, depression, and cravings may persist.[39]
• Post-Acute Withdrawal Syndrome (PAWS): Some individuals may experience lingering psychological symptoms, such as mood swings, depression, and sleep disturbances, for weeks or months.[42]

Management of tramadol withdrawal should be medically supervised. The safest approach is a gradual tapering of the dose over several weeks or months to allow the body to slowly readjust, minimizing the severity of withdrawal symptoms.[1] For more severe cases, especially in a detoxification setting, adjunctive medications may be used to manage specific symptoms.

Clonidine can help alleviate autonomic symptoms like sweating and anxiety, while benzodiazepines (used cautiously) can treat restlessness. Antidepressants may be considered for managing persistent mood disturbances.[42]

Regulatory Status and Global Market Presence

The regulatory journey and global adoption of tramadol reflect its complex identity as both a useful analgesic and a substance with significant abuse potential.

A. Controlled Substance Scheduling (United States)

Tramadol was first approved by the FDA in 1995 and marketed as a non-controlled prescription drug.[38] This classification was based on pre-market data suggesting a low potential for abuse. However, over the subsequent two decades, post-marketing surveillance, law enforcement data, and clinical reports revealed a substantial and growing problem with tramadol diversion, abuse, and dependence.[38]

This accumulation of real-world evidence prompted regulatory re-evaluation. On August 18, 2014, the U.S. Drug Enforcement Administration (DEA) issued a Final Rule that officially placed tramadol and all products containing it into Schedule IV of the Controlled Substances Act (CSA).[11]

A Schedule IV classification is defined for drugs with a low potential for abuse and a low risk of dependence relative to Schedule III substances.[48] Other drugs in this schedule include alprazolam (Xanax), diazepam (Valium), and zolpidem (Ambien).[50] The scheduling of tramadol imposed full federal regulatory controls applicable to Schedule IV substances, including:

• DEA Registration: All entities that manufacture, distribute, prescribe, or dispense tramadol must be registered with the DEA.[45]
• Inventory Requirements: Registrants were required to take an inventory of all tramadol stock on the date the rule became effective.[45]
• Prescription Requirements: Prescriptions for tramadol became subject to federal controls, including a limit of five refills within a six-month period from the date the prescription was issued.[45]
• Labeling: Manufacturers were required to print the "C-IV" designation on all commercial containers.[46]

This regulatory shift from a non-controlled to a scheduled substance nearly 20 years after its initial approval marks a significant chapter in pharmacovigilance, demonstrating how post-market data can fundamentally alter the legal and clinical landscape of a medication.

B. International Brand Names

Tramadol is a globally successful pharmaceutical, marketed under a vast number of brand names in countries around the world. It is available as a single-ingredient product and in numerous fixed-dose combination products, typically with non-opioid analgesics like paracetamol (acetaminophen) or NSAIDs.

• United States Brand Names: Common brand names in the U.S. include Ultram, Ultram ER, Conzip, and Qdolo. The combination product with acetaminophen is sold as Ultracet.[1]
• International Brand Names: The global market features a wide array of brand names, highlighting its widespread use. A selection of these is presented in the table below.

Table 4: Selected International Brand Names for Tramadol

Country/Region	Brand Name(s)	Combination Product	Source Snippet(s)
United Kingdom	Zydol, Zamadol, Maxitram, Marol, Tradorec	No	52
Canada	Zytram, Tridural, Ralivia, Durela	No	1
Germany	Tramal, Tramundin, Contramal, Nobligan	No	9
Australia	Tramal, Zydol, Tramahexal	Yes (with Paracetamol)	54
France	Contramal, Topalgic, Ixprim	Yes (with Paracetamol)	53
India	Contramal, Tramazac, Supridol, Domadol	Yes (with Paracetamol, etc.)	54
Mexico	Tradol, Nobligan, Sinergix, Trexol	Yes (with Paracetamol, Ketorolac)	53
Brazil	Tramal, Sylador, Tramadon, Dorless	Yes (with Paracetamol)	53
South Africa	Tramal, Tramacet, Trepiline	Yes (with Paracetamol)	53

This table is not exhaustive but represents a sample of the numerous brand names available globally.

Conclusion

Tramadol occupies a unique and complex space in the landscape of pain management. It is not a conventional opioid, nor is it a simple SNRI antidepressant; it is a true pharmacological hybrid, a fact that defines both its therapeutic utility and its intricate risk profile. Its dual mechanism of action—weak µ-opioid agonism synergistically combined with serotonin and norepinephrine reuptake inhibition—provides a multimodal analgesic effect that is effective across a broad range of pain states, from acute post-operative pain to chronic neuropathic conditions.

However, this unique pharmacology is also the source of its distinct risks. The clinical effect of tramadol is critically dependent on its metabolic conversion to the potent M1 metabolite by the CYP2D6 enzyme. The high degree of genetic polymorphism in this enzyme means that the same dose can produce vastly different outcomes in different individuals, ranging from therapeutic failure in poor metabolizers to life-threatening toxicity in ultra-rapid metabolizers. This pharmacogenomic variability is a crucial consideration for prescribers and is the scientific basis for the drug's most severe warnings and contraindications, particularly in the pediatric population.

Furthermore, tramadol's SNRI activity introduces risks not typically associated with traditional opioids, namely a dose-dependent risk of seizures and the potential for serotonin syndrome, a life-threatening drug interaction. Its history, from a non-controlled substance to a DEA Schedule IV drug, serves as a powerful lesson in pharmacovigilance, illustrating how real-world evidence of abuse and dependence can reshape the regulatory and clinical perception of a medication over time.

Ultimately, the safe and effective use of tramadol requires a nuanced understanding of its complete profile. Clinicians must weigh its versatile analgesic benefits against a complex set of risks that include not only addiction and respiratory depression but also seizures, serotonin syndrome, and genetically-determined toxicity. A thorough patient assessment, careful dose titration, awareness of drug interactions, and continuous monitoring are paramount to navigating the fine line between providing effective pain relief and ensuring patient safety with this distinctive dual-action analgesic.

Works cited

1. Tramadol: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 21, 2025, https://go.drugbank.com/drugs/DB00193
2. CAS 27203-92-5: Tramadol - CymitQuimica, accessed July 21, 2025, https://cymitquimica.com/cas/27203-92-5/
3. Tramadol - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed July 21, 2025, https://www.ncbi.nlm.nih.gov/books/NBK501260/
4. 27203-92-5 | CAS DataBase - ChemicalBook, accessed July 21, 2025, https://m.chemicalbook.com/CASEN_27203-92-5.htm
5. (tramadol hydrochloride) Tablets Full Prescribing Information DESCRIPTION ULTRAM - accessdata.fda.gov, accessed July 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020281s032s033lbl.pdf
6. 27203-92-5 CAS MSDS (Tramadol) Melting Point Boiling Point Density CAS Chemical Properties - ChemicalBook, accessed July 21, 2025, https://www.chemicalbook.com/ChemicalProductProperty_US_CB7104738.aspx
7. Tramadol | C16H25NO2 | CID 33741 - PubChem, accessed July 21, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/33741
8. Pharmacology of tramadol. - PharmGKB, accessed July 21, 2025, https://www.pharmgkb.org/literature/11360524
9. Tramadol - Wikipedia, accessed July 21, 2025, https://en.wikipedia.org/wiki/Tramadol
10. Clinical pharmacology of tramadol - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/15509185/
11. Tramadol - StatPearls - NCBI Bookshelf, accessed July 21, 2025, https://www.ncbi.nlm.nih.gov/books/NBK537060/
12. Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review - :::::Pain Physician:::::, accessed July 21, 2025, https://www.painphysicianjournal.com/current/pdf?article=MjM3OA%3D%3D&journal=89
13. How and when to take tramadol - NHS, accessed July 21, 2025, https://www.nhs.uk/medicines/tramadol/how-and-when-to-take-tramadol/
14. Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review. - DrugBank, accessed July 21, 2025, https://go.drugbank.com/articles/A173980
15. CONZIP (tramadol hydrochloride) - accessdata.fda.gov, accessed July 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022370s015lbl.pdf
16. Tramadol Hydrochloride Monograph for Professionals - Drugs.com, accessed July 21, 2025, https://www.drugs.com/monograph/tramadol-hydrochloride.html
17. Ultram, ConZip (tramadol) dosing, indications, interactions, adverse effects, and more, accessed July 21, 2025, https://reference.medscape.com/drug/ultram-conzip-tramadol-343324
18. Label: Tramadol hydrochloride tablet, coated - DailyMed, accessed July 21, 2025, https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9893b6c0-fe47-4e56-8857-d3a5a888b9fd
19. Tramadol Tablets: Package Insert / Prescribing Information - Drugs.com, accessed July 21, 2025, https://www.drugs.com/pro/tramadol-tablets.html
20. Tramadol: MedlinePlus Drug Information, accessed July 21, 2025, https://medlineplus.gov/druginfo/meds/a695011.html
21. Tramadol (oral route) - Side effects & dosage - Mayo Clinic, accessed July 21, 2025, https://www.mayoclinic.org/drugs-supplements/tramadol-oral-route/description/drg-20068050
22. Postoperative pain Active Not Recruiting Phase 3 Trials for Tramadol (DB00193) - DrugBank, accessed July 21, 2025, https://go.drugbank.com/indications/DBCOND0022333/clinical_trials/DB00193?phase=3&status=active_not_recruiting
23. Pain Completed Phase 4 Trials for Tramadol (DB00193) | DrugBank Online, accessed July 21, 2025, https://go.drugbank.com/indications/DBCOND0012160/clinical_trials/DB00193?phase=4&status=completed
24. Tramadol Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 21, 2025, https://www.drugs.com/dosage/tramadol.html
25. TramadolHub - 05/29/2018 - FDA, accessed July 21, 2025, https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tramadolhub-05292018
26. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022, accessed July 21, 2025, https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm
27. Tramadol Drug Interactions To Be Aware Of - Crossroads Treatment Centers, accessed July 21, 2025, https://www.crossroadstreatmentcenters.com/tramadol-drug-interactions-to-be-aware-of/
28. Tramadol Use in Pediatric Surgery: Trends After the Food and Drug Administration Black-Box Warning - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/35944445/
29. Tramadol Disease Interactions - Drugs.com, accessed July 21, 2025, https://www.drugs.com/disease-interactions/tramadol.html
30. Taking tramadol with other medicines and herbal supplements - NHS, accessed July 21, 2025, https://www.nhs.uk/medicines/tramadol/taking-tramadol-with-other-medicines-and-herbal-supplements/
31. The 12 Tramadol Interactions You'll Want to Avoid - GoodRx, accessed July 21, 2025, https://www.goodrx.com/tramadol/interactions
32. Tramadol Interactions Checker - Drugs.com, accessed July 21, 2025, https://www.drugs.com/drug-interactions/tramadol.html
33. Tramadol poisoning and its management and complications: a scoping review - PMC, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10406095/
34. Tramadol Overdose: How Much is Too Much? OD Symptoms & Treatment, accessed July 21, 2025, https://www.therecoveryvillage.com/tramadol-addiction/tramadol-overdose/
35. A review on tramadol toxicity: mechanism of action, clinical presentation, and treatment, accessed July 21, 2025, https://d-nb.info/1233150294/34
36. Tramadol Overdose: Symptoms & What to Do | DrugAbuse, accessed July 21, 2025, https://drugabuse.com/opioids/tramadol/overdose/
37. Poison Control, accessed July 21, 2025, https://www.poison.org/
38. TRAMADOL (Trade Names: Ultram®, Ultracet®) - DEA Diversion Control Division, accessed July 21, 2025, https://www.deadiversion.usdoj.gov/drug_chem_info/tramadol.pdf
39. Tramadol Detox: Withdrawal Symptoms & Timeline - Laguna Treatment Center, accessed July 21, 2025, https://lagunatreatment.com/drug-abuse/opioids/tramadol/withdrawal/
40. Tramadol Addiction: Symptoms, Causes, Effects, Treatment And Prevention, accessed July 21, 2025, https://whitelightbh.com/resources/drug-addiction/tramadol/
41. Tramadol Withdrawal Symptoms, Timeline & Detox Treatment - American Addiction Centers, accessed July 21, 2025, https://americanaddictioncenters.org/opioids/tramadol/withdrawal-detox
42. Tramadol Withdrawal & Detox: Symptoms, Timeline & Treatment, accessed July 21, 2025, https://www.recoverykansascity.com/addiction/opioids-and-opiates/withdrawal-from-tramadol/
43. The Tramadol Withdrawal Timeline - Orlando Recovery Center Drug & Alcohol Rehab, accessed July 21, 2025, https://www.orlandorecovery.com/drug-addiction-resources/tramadol-addiction/withdrawal-timeline/
44. Tramadol Dependence in a Patient With No Previous Substance History - PMC, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2882815/
45. DEA Tramadol - Schedule IV Controlled Substance, accessed July 21, 2025, https://www.doh.wa.gov/Portals/1/Documents/2300/2015/DEATramadol.pdf
46. DEA Classifies Tramadol a Controlled Substance - Florida Board of Pharmacy, accessed July 21, 2025, https://floridaspharmacy.gov/dea-classifies-tramadol-a-controlled-substance/
47. Schedule of controlled substances: placement of tramadol into schedule IV. Final rule - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/25016619/
48. DEA makes tramadol a Schedule IV drug, accessed July 21, 2025, https://www.ncmedboard.org/resources-information/professional-resources/publications/forum-newsletter/article/dea-makes-tramadol-a-schedule-iv-drug
49. Prescription of Controlled Substances: Benefits and Risks - StatPearls - NCBI Bookshelf, accessed July 21, 2025, https://www.ncbi.nlm.nih.gov/books/NBK537318/
50. Drug Scheduling - DEA.gov, accessed July 21, 2025, https://www.dea.gov/drug-information/drug-scheduling
51. Tramadol Information - FDA, accessed July 21, 2025, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tramadol-information
52. Tramadol: strong painkiller to treat severe pain - NHS, accessed July 21, 2025, https://www.nhs.uk/medicines/tramadol/
53. TraMADol | Drug Lookup | Pediatric Care Online - AAP Publications, accessed July 21, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5839/TraMADol
54. Tramadol (International database) - Drugs.com, accessed July 21, 2025, https://www.drugs.com/international/tramadol.html